{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-032379","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2024-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.052950+00:00","generated_at":"2026-06-05T00:35:09.257903+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Quoin Pharma raises $6.5M via public offering; FDA clears teen enrollment in Netherton Syndrome trials","bullets":["Raised $6.5M gross from public offering of ADSs, pre-funded and Series D/E warrants at $1.60 combined per unit.","Repriced 638,834 existing warrants from $13.20/$12.00 to $1.60 per ADS; extended expiration to March 7, 2029.","FDA cleared recruitment of teen subjects (14+) into QRX003 trials for Netherton Syndrome, first non-adult inclusion under open IND.","Teens on off-label systemic therapy eligible for open-label study; others eligible for placebo-controlled study.","Net proceeds for general corporate purposes; offering closed March 7, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-032379","json":"https://secwatch.observer/filing/0001104659-24-032379.json","markdown":"https://secwatch.observer/filing/0001104659-24-032379.md","text":"https://secwatch.observer/filing/0001104659-24-032379.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465924032379/0001104659-24-032379-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465924032379/tm248307d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T00:35:09.257903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13b47dadb319b3f409d8604e0ba261b506922b91","claim":"Quoin Pharmaceuticals, Ltd. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at cash fee of 7.0% of the aggregate gross proceeds (effective 2024-03-04).","evidence_excerpt":"Pursuant to that certain placement agency agreement, dated March 4, 2024, by and between the Company and the Placement Agent (the \"Placement Agency Agreement\"), the Placement Agent was paid a cash fee of 7.0% of the aggregate gross proceeds to the Company from the sale of the ADSs, Pre Funded-Funded Warrants and Warrants in the Offering and the Company reimbursed the Placement Agent for (i) non-accountable expenses in an amount of 1.0% of the aggregate gross proceeds raised in the Offering and (ii) accountable expenses of the Placement Agent of $125,000 related to the legal fees.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465924032379/0001104659-24-032379-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"A.G.P./Alliance Global Partners"},{"label":"Value","value":"cash fee of 7.0% of the aggregate gross proceeds"},{"label":"Effective","value":"2024-03-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}